GADD45α-targeted suicide gene therapy driven by synthetic CArG promoter E9NS sensitizes NSCLC cells to cisplatin, resveratrol, and radiation regardless of p53 status

Shi Q, Sutariya V, Varghese Gupta S, Bhatia D

OncoTargets and Therapy 2019, 12:3161-3170

Published Date: 26 April 2019